TOKYO, May 27, 2022 – (JCN Newswire) – Eisai Co., Ltd. announced today that it…
HONG KONG, May 27, 2022 – (ACN Newswire) – On April 26, 2022, the expedition…
Nusa Dua, Bali, May 27, 2022 – (ACN Newswire) – At the 2022 Global Platform…
STRASBOURG, France–(BUSINESS WIRE)–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops…
RiskMeter provides structure-level location information when assessing a property’s exposure to natural disasters IRVINE, Calif.–(BUSINESS…
TOKYO, May 27, 2022 – (JCN Newswire) – The Ajinomoto Foundation, Sysmex Corporation, and NEC…
HONG KONG, May 27, 2022 – (ACN Newswire) – Hong Kong has been named as…
SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a…
BMF-219 is the first investigational menin inhibitor in clinical development to show potential as a…
– First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed…
PRESS RELEASE Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO)…
Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1…
IMM-1-104 strongly inhibits tumor growth in an animal model of KRAS-G12V mutant pancreatic cancer Preclinical…
– Initial Data to be Presented from GSK-Sponsored Phase 1/2 Study Evaluating Nirogacestat in Combination…
Updated MCL and CLL data from the CIRLL study are encouraging and continue to improve…
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced…
Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete…
Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase…
Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations…
Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ASCO abstract…